U.S. drugmakers step up supplies as India battles COVID-19 surge – Reuters

The logo of Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo
April 26 (Reuters) – U.S. drugmaker Merck & Co (MRK.N) joined Gilead Sciences (GILD.O)on Tuesday in lending support to India as the world's second-most populous country scrambles to address drug shortages and bring a raging new wave of COVID-19 cases under control.
Gilead said it would give India at least 450,000 vials of its antiviral drug remdesivir, while Merck said it was partnering with five Indian generic drugmakers to expand production and access to its experimental COVID-19 drug molnupiravir.
With the death toll from COVID-19 racing towards the 200,000-mark in India, medical supplies from across the world are being flown into the country to helpoverburdened hospitals struggling with a severe shortage of life-saving oxygen anddrugs.
Nations including Britain, Germany and the United States have pledged support, while the World Health Organization said it was working to deliver 4,000 oxygen concentrators, calling the situation in India "beyond heartbreaking". read more
In addition, India expects to secure the biggest chunk of the 60 million AstraZeneca (AZN.L) COVID-19 vaccine doses that the United States will share globally, two Indian government sources told Reuters. read more
Gilead said on Monday it would help boost the production of remdesivir in India, where the drug is approved for restricted emergency use to treat severe COVID-19 cases, by offering technical assistance to its manufacturing partners.
Seven Indian companies have licensed the drug from Gilead, with a total installed capacity of about 3.9 million units per month. Gilead said the companies were scaling up their batch sizes and adding new manufacturing facilities and local contract manufacturers.
Hospitals are facing supply shortages of remdesivir due to indiscriminate use. The drug is being sold at over 10 times its listed price in the black market, stoking fears of hoarding as people queue up outside clinics and millions take to social media to secure supplies.
Earlier this month, India banned the export of the drug and the active pharmaceutical ingredients (API) used to make it. read more
The WHO in November issued a conditional recommendation against the use of remdesivir in hospitalised patients due to doubts about its effectiveness in treating COVID-19, but India has continued to use it.
A senior Indian government health official said last week that remdesivir is only for those patients who need oxygen. "I am appealing that the hype over this medicine should be decreased, and it should be used in a rational manner," Vinod Kumar Paul said.
Merck said on Tuesday its partnership with Indian drugmakers, including Cipla Ltd (CIPL.NS) and Sun Pharmaceutical Industries Ltd (SUN.NS), will give the companies license to supply molnupiravir to India and more than 100 low- and middle-income countries after the treatment is authorized. read more
Merck also said it would donate more than $5 million worth of oxygen-production equipment, masks, hand sanitizers and financial aid to India.
Our Standards: The Thomson Reuters Trust Principles.
Keep up with the latest medical breakthroughs, healthcare trends, pharmaceutical news and more.
Subscribe to our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved


Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart